Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio.
Market Cap | 9.277 Billion | Shares Outstanding | 87.501 Million | Avg 30-day Volume | 1.005 Million |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.6 |
Price to Revenue | 0.0 | Debt to Equity | 1.2824 | EBITDA | 0 |
Price to Book Value | 7.9772 | Operating Margin | 0.0 | Enterprise Value | 5.921 Billion |
Current Ratio | 5.563 | EPS Growth | 0 | Quick Ratio | 4.817 |
1 Yr BETA | 1.0203 | 52-week High/Low | 107.03 / 61.28 | Profit Margin | 0.0 |
Operating Cash Flow Growth | 0.0 | Altman Z-Score | 1.1629 | Free Cash Flow to Firm | -53.586 Million |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
0 | 2022-06-02 | 2 | |
|
75,194 | 2022-06-02 | 2 | |
BROWN RYAN EDWARD SVP, GENERAL COUNSEL |
|
25,841 | 2022-06-01 | 3 |
|
153,547 | 2022-03-07 | 2 | |
|
17,433 | 2022-03-07 | 2 | |
|
24,548 | 2022-03-07 | 1 | |
|
3,133,396 | 2022-03-07 | 1 | |
|
19,882 | 2022-03-07 | 1 | |
|
12,322 | 2022-03-07 | 3 | |
|
70,099 | 2022-03-04 | 1 | |
RODINO-KLAPAC LOUISE HEAD OF R&D, CSO |
|
120,111 | 2022-03-04 | 4 |
ESTEPAN IAN MICHAEL CHIEF FINANCIAL OFFICER |
|
80,671 | 2022-03-04 | 3 |
INGRAM DOUGLAS S PRESIDENT & CEO |
|
365,082 | 2021-11-17 | 1 |
|
13,431 | 2021-03-03 | 0 | |
O'NEILL GILMORE NEIL EVP, R&D & CMO |
|
89,070 | 2021-03-03 | 0 |
BRATICA JOSEPH PRINCIPAL FINANCIAL OFFICER |
|
No longer subject to file | 2020-12-11 | 0 |
HOWTON DAVID T EVP, GENERAL COUNSEL |
|
31,871 | 2020-06-22 | 0 |
MAHATME SANDESH EVP, CFO & CBO |
|
32,272 | 2020-05-11 | 0 |
|
9,126 | 2020-02-28 | 0 | |
CUMBO ALEXANDER EVP, CHIEF COMMERCIAL OFFICER |
|
12,008 | 2020-02-28 | 0 |
O'NEILL GILMORE NEIL EVP, R&D & CMO O'NEILL GILMORE NEIL EVP, R&D & CMO |
|
0 | 2019-03-04 | 0 |
RUFF SHAMIM SVP, CHIEF REGULATORY AFFAIRS |
|
31,936 | 2018-05-22 | 0 |
BASI GURIQBAL S. SVP, CHIEF SCIENTIFIC OFFICER |
|
0 | 2018-03-05 | 0 |
|
71,229 | 2017-08-03 | 0 | |
STEHMAN-BREEN CATHERINE SVP, CHIEF MEDICAL OFFICER |
|
0 | 2017-04-03 | 0 |
|
2,000 | 2017-03-10 | 0 | |
WOOD JOAN VP, HUMAN RESOURCES |
|
14,926 | 2016-09-20 | 0 |
APHALE JAYANT VP, TECHNICAL OPERATIONS |
|
No longer subject to file | 2016-09-19 | 0 |
|
42,830 | 2016-03-14 | 0 | |
|
8,166 | 2016-02-29 | 0 | |
|
6,333 | 2015-02-27 | 0 | |
|
67,194 | 2015-02-27 | 0 | |
CHRISTOPHER NISHAN GARABEDIAN PRESIDENT AND CEO |
|
402,552 | 2015-02-27 | 0 |
KRIEG ARTHUR M SVP, CHIEF SCIENTIFIC OFFICER |
|
0 | 2014-01-13 | 0 |
|
0 | 2013-06-04 | 0 | |
JACOBSEN MICHAEL A VP OF FINANCE AND PAO |
|
7,500 | 2012-08-23 | 0 |
MILE MELINDA G CONTROLLER AND PAO |
|
0 | 2011-08-31 | 0 |
TOSHAV BRACHA EPHRAT SR VP & GENERAL COUNSEL |
|
0 | 2011-08-31 | 0 |
LINSLEY PETER S SVP & CHIEF SCIENTIFIC OFFICER |
|
0 | 2011-05-16 | 0 |
BOYLE J DAVID II CEO |
|
70,282 | 2010-08-27 | 0 |
WELLER DWIGHT D SR. VP CHEMISTRY & MFG. |
|
0 | 2010-08-23 | 0 |
IVERSEN PATRICK L SR VP OF RESEARCH & DEVLOPMENT |
|
0 | 2010-08-23 | 0 |
SHREWSBURY STEPHEN B SVP/REGULATORY AFFAIRS |
|
0 | 2010-08-23 | 0 |
MEDEIROS PAUL SVP BUSINESS DEVELOPMENT |
|
0 | 2010-08-23 | 0 |
JOHNSON GRAHAM SR VP PRECLINICAL DEV & RSRCH |
|
0 | 2010-08-23 | 0 |
HUDSON LESLIE FORMER CEO |
|
384,559 | 2010-07-30 | 0 |
HAYWOOD CHERYL |
|
8,329,126 | 2010-03-16 | 0 |
|
2,935,696 | 2010-03-16 | 0 | |
|
No longer subject to file | 2010-03-04 | 0 | |
KOLE RYSZARD SVP/DISCOVERY RESEARCH |
|
1,862,926 | 2010-02-09 | 0 |
|
No longer subject to file | 2009-08-21 | 0 | |
|
9,914,211 | 2009-05-31 | 0 | |
FORREST K MICHAEL OUTSIDE DIRECTOR |
|
15,000 | 2009-05-19 | 0 |
|
5,000 | 2009-05-19 | 0 | |
|
0 | 2009-03-31 | 0 | |
|
500 | 2008-05-20 | 0 | |
OHANLEY PETER D SR. VICE PRESIDENT |
|
0 | 2008-02-28 | 0 |
|
15,446 | 2008-02-02 | 0 | |
TIMMINS ALAN P PRESIDENT & COO |
|
71,382 | 2008-02-02 | 0 |
|
78,334 | 2007-05-22 | 0 | |
|
79,334 | 2007-05-22 | 0 | |
BURGER DENIS R CHIEF EXECUTIVE OFFICER |
|
1,180,000 | 2007-04-03 | 0 |
HORN JOSEPH B VICE PRESIDENT OF CARDIOLOGY |
|
100,000 | 2006-03-22 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
SAREPTA THERAPEUTICS INC SRPT | 2022-08-08 22:15:06 UTC | 2.051 | 0.269 | 2000000 |
SAREPTA THERAPEUTICS INC SRPT | 2022-08-08 21:45:05 UTC | 2.051 | 0.269 | 2000000 |
SAREPTA THERAPEUTICS INC SRPT | 2022-08-08 21:15:05 UTC | 2.051 | 0.269 | 2000000 |
SAREPTA THERAPEUTICS INC SRPT | 2022-08-08 20:45:05 UTC | 2.057 | 0.263 | 2000000 |
SAREPTA THERAPEUTICS INC SRPT | 2022-08-08 20:15:05 UTC | 2.057 | 0.263 | 2000000 |
SAREPTA THERAPEUTICS INC SRPT | 2022-08-08 19:45:03 UTC | 2.057 | 0.263 | 2000000 |
SAREPTA THERAPEUTICS INC SRPT | 2022-08-08 19:15:04 UTC | 2.057 | 0.263 | 2000000 |
SAREPTA THERAPEUTICS INC SRPT | 2022-08-08 18:45:04 UTC | 2.057 | 0.263 | 2000000 |
SAREPTA THERAPEUTICS INC SRPT | 2022-08-08 18:15:05 UTC | 2.057 | 0.263 | 2000000 |
SAREPTA THERAPEUTICS INC SRPT | 2022-08-08 17:45:04 UTC | 2.057 | 0.263 | 2000000 |
SAREPTA THERAPEUTICS INC SRPT | 2022-08-08 17:15:04 UTC | 2.057 | 0.263 | 2000000 |
SAREPTA THERAPEUTICS INC SRPT | 2022-08-08 16:45:03 UTC | 2.0555 | 0.2645 | 2000000 |
SAREPTA THERAPEUTICS INC SRPT | 2022-08-08 16:15:03 UTC | 2.0555 | 0.2645 | 2000000 |
SAREPTA THERAPEUTICS INC SRPT | 2022-08-08 15:45:04 UTC | 2.0555 | 0.2645 | 1800000 |
SAREPTA THERAPEUTICS INC SRPT | 2022-08-08 15:15:05 UTC | 2.0555 | 0.2645 | 1800000 |
SAREPTA THERAPEUTICS INC SRPT | 2022-08-08 14:45:03 UTC | 2.0555 | 0.2645 | 1800000 |
SAREPTA THERAPEUTICS INC SRPT | 2022-08-08 14:15:04 UTC | 2.0555 | 0.2645 | 1800000 |
SAREPTA THERAPEUTICS INC SRPT | 2022-08-08 13:45:05 UTC | 2.0457 | 0.2743 | 1800000 |
SAREPTA THERAPEUTICS INC SRPT | 2022-08-08 13:15:04 UTC | 2.0457 | 0.2743 | 1600000 |
SAREPTA THERAPEUTICS INC SRPT | 2022-08-08 12:45:05 UTC | 2.0457 | 0.2743 | 1600000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
American Century Quantitative Equity Funds, Inc.- AC Alternatives Equity Market Neutral Fund | SRPT | -968.0 shares, $-124910.72 | 2019-12-31 | N-PORT |
American Century Quantitative Equity Funds, Inc.- AC Alternatives Disciplined Long Short Fund | SRPT | -705.0 shares, $-90973.2 | 2019-12-31 | N-PORT |
American Century Quantitative Equity Funds, Inc.- Core Equity Plus Fund | SRPT | -2819.0 shares, $-212327.08 | 2019-09-30 | N-PORT |
AGF Investments Trust- AGFIQ U.S. Market Neutral Value Fund | SRPT | -22.0 shares, $-3089.46 | 2020-09-30 | N-PORT |
American Century Quantitative Equity Funds, Inc.- NT Core Equity Plus Fund | SRPT | -9436.0 shares, $-710719.52 | 2019-09-30 | N-PORT |
Jackson Variable Series Trust- JNL/Nicholas Convertible Arbitrage Fund | SRPT | -9960.0 shares, $-974287.2 | 2020-03-31 | N-PORT |
FundVantage Trust- Gotham Enhanced Index Plus Fund | SRPT | -47.0 shares, $-4597.54 | 2020-03-31 | N-PORT |
FundVantage Trust- Gotham Defensive Long Fund | SRPT | -33.0 shares, $-3228.06 | 2020-03-31 | N-PORT |
FundVantage Trust- Gotham Index Plus All-Cap Fund | SRPT | -87.0 shares, $-8510.34 | 2020-03-31 | N-PORT |
INVESTMENT MANAGERS SERIES TRUST- AAM HIMCO Global Enhanced Dividend Fund | SRPT | -854.0 shares, $-63648.62 | 2021-03-31 | N-PORT |
Prudential Investment Portfolios 12- PGIM QMA Long-Short Equity Fund | SRPT | -800.0 shares, $-73984.0 | 2021-09-30 | N-PORT |
Advanced Series Trust- AST QMA U.S. Equity Alpha Portfolio | SRPT | -12700.0 shares, $-1174496.0 | 2021-09-30 | N-PORT |
FundVantage Trust- Gotham Hedged Plus Fund | SRPT | -2572.0 shares, $-200924.64 | 2022-03-31 | N-PORT |
AdvisorShares Trust- AdvisorShares Dorsey Wright Short ETF | SRPT | -3179.0 shares, $-248343.48 | 2022-03-31 | N-PORT |
Calamos Investment Trust/IL- Calamos Market Neutral Income Fund | SRPT | -174500.0 shares, $-12619840.0 | 2022-04-30 | N-PORT |
Series Portfolios Trust- Weiss Alternative Multi-Strategy Fund | SRPT | -148.0 shares, $-10703.36 | 2022-04-30 | N-PORT |
VANGUARD TRUSTEES' EQUITY FUND- VANGUARD ALTERNATIVE STRATEGIES FUND | SRPT | -1393.0 shares, $-100741.76 | 2022-04-30 | N-PORT |